DOCSLIB.ORG

Voss Atopic Dermatitis and Itch

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Voss Atopic Dermatitis and Itch DISCLOSURES 2018 MOAPA Primary Care Update Conference ATOPIC This speaker has no disclosures to Susan T. Voss DNP, DERMATITIS declare FNP-BC, DCNP, FAANP & ITCH Riverside Dermatology OBJECTIVES ATOPIC DERMATITIS Atopic Dermatitis Itch/Pruritus ▪ Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease of unknown origin ▪ Describe the pathophysiology of ▪ Define itch/pruritus ▪ Commonly referred to as eczema AD ▪ Describe the pathophysiology of ▪ Usually starts in early infancy. ▪ Discuss the presentation and itch ▪ In US impacts 10-12% of children diagnostic workup ▪ List/Describe the etiological ▪ Present treatment options classifications of chronic pruritus ▪ Affects a substantial number of adults. ▪ In US 0.9% ▪ Present an algorithm for assessment of itch ▪ AD is commonly associated with elevated levels of immunoglobulin ▪ Discuss pharmacologic and E (IgE). nonpharmacologic treatment options ATOPIC DERMATITIS: ATOPIC DERMATITIS: PATHOPHYSIOLOGY PATHOPHYSIOLOGY ▪Atopic dermatitis arises because of a complex Two main hypotheses have been proposed regarding the interaction of genetic and environmental development of inflammation that leads to AD. factors. ▪The first suggests a primary immune dysfunction resulting in IgE sensitization, allergic inflammation, and a secondary ▪These include defects in skin barrier function epithelial barrier disturbance. making the skin more susceptible to irritation ▪The second proposes a primary defect in the epithelial barrier by soap and other contact irritants, the leading to secondary immunologic dysregulation and resulting in inflammation. weather, temperature and non-specific triggers. ATOPIC DERMATITIS: ATOPIC DERMATITIS: PATHOPHYSIOLOGY STAGES ▪The fact that AD is the first disease to present in a ▪ THREE STAGES series of allergic diseases—including food allergy, ▪ Infantile ▪ 2 months to 2 years of age asthma, and allergic rhinitis, in order—has given rise ▪ Childhood to the “atopic march” theory, which suggests that AD ▪ 2 to 10 years is part of a progression that may lead to subsequent ▪ Adolescent/Adult allergic disease at other epithelial barrier surfaces. ▪ >10 years In all stages, pruritus is the hallmark. Itching often precedes the appearance of lesions; hence the concept that AD is “the itch that rashes” ATOPIC DERMATITIS AD DIAGNOSTIC CRITERIA: CLASSES OF LESIONS MAJOR ▪ Acute ▪ Intensely pruritic erythematous papules and vesicles overlying erythematous skin; frequently associated with extensive excoriations and MUST HAVE THREE OF THE FOLLOWING erosions accompanied by serous exudates • Pruritus ▪ Subacute • Typical morphology and distribution ▪ Erythema, excoriation, and scaling • Flexural lichenification in adults ▪ Chronic • Facial and extensor involvement in infancy ▪ Thickened plaques of skin, accentuated skin markings (lichenification), • Chronic or chronically relapsing dermatitis fibrotic papules (prurigo nodularis); possible coexistence of all 3 types of • Personal or family history of atopic disease lesions in chronic atopic dermatitis • Asthma, allergic rhinitis, atopic dermatitis MUST ALSO HAVE AT LEAST THREE: ▪ Xerosis ▪ Nipple eczema ▪ Ichthyosis/hyperlinear palms/keratosis pilaris ▪ Cheilitis ▪ IgE reactivity (immediate skin test reactivity, AD ▪ Recurrent conjunctivitis AD RAST test positive) DIAGNOSTIC ▪ Dennie–Morgan infraorbital fold DIAGNOSTIC ▪ Elevated serum IgE CRITERIA: ▪ Keratoconus CRITERIA: ▪ Early age of onset MINOR ▪ Anterior subcapsular cataracts ▪ Tendency for cutaneous infections MINOR Orbital darkening (especially Staphylococcus aureus and herpes CONTINUED ▪ simplex virus) ▪ Facial pallor/facial erythema ▪ Tendency to nonspecific hand/foot dermatitis ATOPIC DERMATITIS: PRESENTATION/HISTORY ▪ Pityriasis alba ▪ Itch when sweating ▪Essential historical features to diagnose: ▪ Intolerance to wool and lipid solvents AD ▪Pruritus DIAGNOSTIC ▪ Perifollicular accentuation CRITERIA: ▪ Food hypersensitivity ▪ Central and most debilitating symptom of AD, incessant ▪ Course influenced by environmental and/or MINOR emotional factors ▪Chronic or relapsing history of disease CONTINUED ▪ White dermatographism or delayed blanch to cholinergic agents ▪ Intermittent course with flares and remissions, often for unexplained reasons. ATOPIC DERMATITIS: AD PRESENTATION PRESENTATION/HISTORY INFANTILE ▪Important historical features to supports the ▪ Infantile AD usually begins with erythema and scaling of the cheeks diagnosis: ▪Early age of onset ▪Atopy: Personal and/or family history ▪ Atopy refers to the genetic tendency to develop allergic diseases such as allergic rhinitis, asthma, and atopic dermatitis. Atopy is typically associated with heightened immune responses to common allergens, especially inhaled allergens and food allergens.(AAAAI) AD PRESENTATION AD PRESENTATION INFANTILE INFANTILE ▪ Extend to the scalp, neck, forehead, wrists, and extensor extremities. ▪ Can be more widely distributed in infants less than one year. Exudative AD PRESENTATION AD PRESENTATION CHILDHOOD CHILDHOOD ▪ Classic locations ▪ Antecubital fossae ▪ antecubital and popliteal fossae, flexor wrists, eyelids, face, and around the neck. ▪ Progresses from the extensor surfaces to flexor. ▪ Lesions are ▪ often lichenified, indurated plaques ▪ African-American patients may have a lichenoid appearance and favor the extensor surfaces. ▪ Intermingled with isolated, excoriated 2–4 mm papules that are scattered more widely over the uncovered skin. ▪ Severe AD with large BSA can lead to growth retardation AD PRESENTATION AD PRESENTATION CHILDHOOD CHILDHOOD ▪ Popliteal Fossae ▪Hand AD ADPRESENTATION PRESENTATION CHILDHOOD CHILDHOOD ▪ Eyelid ▪ Hyperlinear palms AD PRESENTATION AD PRESENTATION CHILDHOOD ADOLESCENT/ADULT ADOLESCENTS ▪ Eruption often involves: ▪ classic antecubital and popliteal fossae ▪ front and sides of the neck ▪ forehead, and area around the eyes AD PRESENTATION AD PRESENTATION ADOLESCENT/ADULT ADOLESCENTS/ADULTS ▪ Neck OLDER ADULTS ▪ Distribution is generally less characteristic ▪ Localized dermatitis may be the predominant feature, especially hand, nipple, or eyelid eczema. ▪ The skin, in general, is dry and somewhat erythematous. Lichenification and prurigo-like papules are common ▪ Papular lesions tend to be dry, slightly elevated, and flat-topped. ▪ Excoriated and often coalesce to form plaques. ▪ Staphylococcal colonization is nearly universal. ▪ In darker-skinned patients, the lesions are often dramatically hyperpigmented, frequently with focal hypopigmented areas related to healed excoriations. AD PRESENTATION AD PRESENTATION ADOLESCENTS/ADULTS ADOLESCENTS/ADULTS ▪ Nipple eczema ▪ Eyelid AD PRESENTATION ATOPIC DERMATITIS: ADOLESCENT/ADULT ASSOCIATED FEATURES ▪ Secondary infection ▪ Pityriasis alba ATOPIC ATOPIC DERMATITIS: DERMATITIS: ASSOCIATED ASSOCIATED FEATURES FEATURES ▪ Dennie-Morgan fold ▪ Cheilitis ATOPIC DERMATITIS: ATOPIC DERMATITIS: ASSOCIATED FEATURES DIAGNOSIS ▪ Keratosis pilaris ▪ Diagnosis is often based on presentation and history of the rash ▪ If necessary a skin biopsy can be performed ▪ A punch biopsy for H&E ▪ Findings are often nonspecific with spongiotic dermatitis AD: GENERAL MANAGEMENT AD: GENERAL MANAGEMENT EDUCATION AND SUPPORT ▪ Education and support EDUCATION AND SUPPORT ▪ Barrier repair ▪ Patient and parent education is critical!! ▪ Antimicrobial therapy ▪ Action Plan or Stepwise Approach ▪ Environmental factors ▪ Resources ▪ National Eczema Association: www.nationaleczema.org ▪ Antipruritics ▪ National Eczema Society: www.eczema.org ▪ Emotional Support ▪ AD impacts the whole family ▪ Sleep deprivation ▪ Burnout with treatment which can be time consuming AD: GENERAL MANAGEMENT AD: GENERAL MANAGEMENT BARRIER REPAIR BARRIER REPAIR ▪ TO BATHE OR NOT TO BATHE MOISTURIZE / BARRIER REPAIR ▪ Bathing with proper moisturization is key ▪ At least twice a day, at least once after bath/shower ▪ Lightly towel dry and apply moisturizer within 3-5 minutes ▪ Ointment and creams preferred over lotion Seals in moisture and allow water to be absorbed through the stratum ▪ ▪ More humectants corneum. ▪ ▪ Lukewarm water Petrolatum ▪ Vaseline, Aquaphor ▪ Avoid fragrance and dyes ▪ Moist wraps ▪ If child wants to “play” in the water do that first ▪ Ceramide based ointments ▪ After applying soap rinse and get out as soon as possible. ▪ Cerave, Cetaphil Restoraderm, Hylatopic Plus (Rx), Eucerin ▪ Only apply soap to armpits, genitalia, and bottom of feet. AD: GENERAL MANAGEMENT AD: GENERAL MANAGEMENT ANTIMICROBIAL THERAPY ENVIRONMENTAL FACTORS ▪ Treat infections with appropriate topical or systemic antibiotic ▪ Avoid external irritants Stress ▪ Key is to decrease chance for infection by reducing nasal ▪ staphylococcal carriage pre-emptively and keeping the skin ▪ Heat decolonized from Staphylococcus. ▪ Sweating ▪ Mupirocin ointment three times a day to each nostril one week out of ▪ Wool each month. ▪ Avoid contact allergens ▪ Bleach water tepid baths twice weekly ▪ Products with common allergens ▪ ½ cup standard bleach to regular size tub (40 gallons) ▪ Fragrance and dyes ▪ Swimming in chlorine based pool ▪ Wipes with methylisothiazolinone ▪ Parents may also be colonized (80%) ▪ Test for allergens when appropriate AD: GENERAL MANAGEMENT AD: TREATMENT ANTIPRURITICS TOPICAL CORTICOSTEROIDS ▪ Oral antihistamines ▪ Lowest potency steroid ▪ Discuss more with itch discussion ▪ Fluocinolone acetonide topical oil, 0.01% ▪ Topical ▪ Derma-Smoothe FS Body Oil ▪ Ice or cool compresses ▪ Mineral oil and ultra-refined peanut oil based ▪ Moisturizers containing
Load more

Recommended publications
  • Autoimmune Associations of Alopecia Areata in Pediatric Population - a Study in Tertiary Care Centre
    IP Indian Journal of Clinical and Experimental Dermatology 2020;6(1):41–44 Content available at: iponlinejournal.com IP Indian Journal of Clinical and Experimental Dermatology Journal homepage: www.innovativepublication.com Original Research Article Autoimmune associations of alopecia areata in pediatric population - A study in tertiary care centre Sagar Nawani1, Teki Satyasri1,*, G. Narasimharao Netha1, G Rammohan1, Bhumesh Kumar1 1Dept. of Dermatology, Venereology & Leprosy, Gandhi Medical College, Secunderabad, Telangana, India ARTICLEINFO ABSTRACT Article history: Alopecia areata (AA) is second most common disease leading to non scarring alopecia . It occurs in Received 21-01-2020 many patterns and can occur on any hair bearing site of the body. Many factors like family history, Accepted 24-02-2020 autoimmune conditions and environment play a major role in its etio-pathogenesis. Histopathology shows Available online 29-04-2020 bulbar lymphocytes surrounding either terminal hair or vellus hair resembling ”swarm of bees” appearance depending on chronicity of alopecia areata. Alopecia areata in children is frequently seen. Pediatric AA has been associated with atopy, thyroid abnormalities and a positive family history. We have done a study to Keywords: find out if there is any association between alopecia areata and other auto immune diseases in children. This Alopecia areata study is an observational study conducted in 100 children with AA to determine any associated autoimmune Auto immunity conditions in them. SALT score helps to assess severity of alopecia areata. Severity of alopecia areata was Pediatric population assessed by SALT score-1. S1- less than 25% of hairloss, 2. S2- 25-49% of hairloss, 3. 3.S3- 50-74% of hairloss.
    [Show full text]
  • The Tumor Necrosis Factor Superfamily Molecule LIGHT Promotes Keratinocyte Activity and Skin Fibrosis Rana Herro1, Ricardo Da S
    ORIGINAL ARTICLE The Tumor Necrosis Factor Superfamily Molecule LIGHT Promotes Keratinocyte Activity and Skin Fibrosis Rana Herro1, Ricardo Da S. Antunes1, Amelia R. Aguilera1, Koji Tamada2 and Michael Croft1 Several inflammatory diseases including scleroderma and atopic dermatitis display dermal thickening, epidermal hypertrophy, or excessive accumulation of collagen. Factors that might promote these features are of interest for clinical therapy. We previously reported that LIGHT, a TNF superfamily molecule, mediated collagen deposition in the lungs in response to allergen. We therefore tested whether LIGHT might similarly promote collagen accumulation and features of skin fibrosis. Strikingly, injection of recombinant soluble LIGHT into naive mice, either subcutaneously or systemically, promoted collagen deposition in the skin and dermal and epidermal thickening. This replicated the activity of bleomycin, an antibiotic that has been previously used in models of scleroderma in mice. Moreover skin fibrosis induced by bleomycin was dependent on endogenous LIGHT activity. The action of LIGHT in vivo was mediated via both of its receptors, HVEM and LTβR, and was dependent on the innate cytokine TSLP and TGF-β. Furthermore, we found that HVEM and LTβR were expressed on human epidermal keratinocytes and that LIGHT could directly promote TSLP expression in these cells. We reveal an unappreciated activity of LIGHT on keratinocytes and suggest that LIGHT may be an important mediator of skin inflammation and fibrosis in diseases such as scleroderma
    [Show full text]
  • Immune Globulin Therapy
    Immune Globulin Therapy Policy Number: Original Effective Date: MM.04.015 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 02/01/2013 Section: Prescription Drugs Place(s) of Service: Outpatient I. Description Intravenous immune globulin (IVIG) is a sterile, highly purified preparation of unmodified immunoglobulins, which are isolated from large pools of human plasma. IVIG is an infusion used to treat patients with inherited or acquired immune deficiencies. It provides passive immunity against infection by increasing a person’s antibody titer and antigen-antibody reaction potential. IVIG supplies a broad spectrum of IgG antibodies against bacterial, viral, parasitic, and mycoplasmal antigens. Subcutaneous immune globulin (Sub-q IG) is FDA approved for the treatment of patients with primary immune deficiency. It is injected under the skin using an infusion pump, which means patients can self-administer the product in a home setting. II. Criteria/Guidelines A. IVIG therapy is covered (subject to Limitations/Exclusions and Administrative Guidelines) for the following indications: 1. Treatment of primary immunodeficiencies, including: a. Congenital agammaglobulinemia ( X-linked agammaglobulinemia) b. Hypogammaglobulinemia c. Common variable immunodeficiency d. X-linked immunodeficiency with hyperimmunoglobulin M e. Severe combined immunodeficiency f. Wiskott-Aldrich syndrome 2. Idiopathic thrombocytopenic purpura (ITP) Immune Globulin Therapy 2 3. Prevention of graft-versus-host disease in non-autologous bone marrow transplant patients age 20 or older in the first 100 days after transplantation 4. Kawasaki syndrome when used in conjunction with aspirin 5. Prevention of infection in: a. HIV-infected pediatric patients b. Bone marrow transplant patients age 20 or older in the first 100 days after transplantation c.
    [Show full text]
  • Subject Index
    52_1107_1136_SI 16.11.2005 9:35 Uhr Seite 1107 Subject Index A – tape 264, 368, 940 α-adjustment 154 AAS, see atomic absorption spectrophotometry adrenocorticotrophic hormone (ACTH) 21 abietic acid 909, 943 adverse drug reaction 401 abrasion 174, 283 aeroallergen 391 absorption through appendage 169 – atopic eczema 391 α-acaridial 329 – avoidance 391 accident 889 aerospace 726 acebutolol hydrochloride 909 African aceclofenac 909 –ebony783 acetaldehyde 943 – mahagony 783 acetone 118, 666 – red padauk wood 783 acetylacetone 697 Agave acetylsalicylic acid 84, 909 – americana 354 Achillea millefolium (yarrow extract) 909 – tequilana 225 aciclovir 909 age 279 acid 110 agent orange 806 – black 48 (CI 65005) 909 AGEP 404 – dye 689 Agfa TSS 355 – halogenated 259 aggravation 204 –hydrochloric261 agricultural worker 272 –nitric261 agriculture 725 –red AICD, see activation-induced cell death – – 14 (azorubine) 909 airborne – – 118 (CI 26410) 909 – allergic contact dermatitis 218, 228, 315, 467, 477, 484, 598, ––359909 627, 654, 788 – violet 17 (CI 42650) 909 – contact urticaria 753, 758 – yellow – irritant contact dermatitis 625 – – 36 (CI 13065, metanil yellow) 909 aircraft manufacture 560 – – 61 (CI 18968) 909 airway symptom 520 acitretin 341 alachlor 953 acneiform alantolactone 55, 789, 909, 954 – folliculitis 229 alclometasone-17,21-dipropionate 909 –lesion265 alclometasone-17-propionate 58 acrodermatitis enteropathica 241 alcohol, see also ethyl 909 acrovesicular dermatitis 401 aldehyde 110, 607, 886 acrylamide 592, 944 algicide 562 acrylate
    [Show full text]
  • Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002
    Department of Health & Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002 CHANGE REQUEST 2149 HEADER SECTION NUMBERS PAGES TO INSERT PAGES TO DELETE Table of Contents 2 1 45-30 - 45-31 2 2 NEW/REVISED MATERIAL--EFFECTIVE DATE: October 1, 2002 IMPLEMENTATION DATE: October 1, 2002 Section 45-31, Intravenous Immune Globulin’s (IVIg) for the Treatment of Autoimmune Mucocutaneous Blistering Diseases, is added to provide limited coverage for the use of IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid (a.k.a., Cicatricial Pemphigoid), and (5) Epidermolysis Bullosa Acquisita. Use J1563 to bill for IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid, and (5) Epidermolysis Bullosa Acquisita. This revision to the Coverage Issues Manual is a national coverage decision (NCD). The NCDs are binding on all Medicare carriers, intermediaries, peer review organizations, health maintenance organizations, competitive medical plans, and health care prepayment plans. Under 42 CFR 422.256(b), an NCD that expands coverage is also binding on a Medicare+Choice Organization. In addition, an administrative law judge may not review an NCD. (See §1869(f)(1)(A)(i) of the Social Security Act.) These instructions should be implemented within your current operating budget. DISCLAIMER: The revision date and transmittal number only apply to the redlined material. All other material was previously published in the manual and is only being reprinted. CMS-Pub.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Effectiveness of Medium-Dose Ultraviolet A1 Phototherapy in Localized Scleroderma
    Pharmacology and therapeutics Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma Ozlem Su1, MD, Nahide Onsun1, MD, Hulya Kapran Onay2, MD, Yeliz Erdemoglu1, MD, Dilek Biyik Ozkaya1, MD, Filiz Cebeci1, MD, and Adnan Somay3, MD 1Department of Dermatology, Abstract Bezmialem Vakif University, Faculty of Background Recently, ultraviolet (UV) A1 phototherapy has been suggested as an effec- 2 Medicine, Neoson Imaging Center, tive treatment for localized scleroderma (LS); however, the optimal dose of UVA1 still has Radiology, and 3Department of not been determined. Pathology, Vakif Gureba Teaching and 2 Research Hospital, Istanbul, Turkey Objective We aimed to evaluate the therapeutic effectiveness of medium-dose (30 J/cm ) UVA1 phototherapy and to show that 13 MHz ultrasound is a valuable tool for assessing Correspondence the results of UVA1 phototherapy in LS. Ozlem Su, MD Methods Thirty-five patients with LS were treated with medium-dose (30 J/cm2) UVA1. Sıgırtmac Sok. No. 21 B blok d. 7 In total, 30–45 treatments and 900–1350 J/cm2 cumulative UVA1 doses were evaluated by Osmaniye Bakirkoy clinical scoring in all patients. In 14 patients, skin thickness was also determined by Istanbul 13 MHz ultrasound examination. Turkey Results In all patients, medium-dose UVA1 therapy softened sclerotic plaques, and E-mail: [email protected] marked clinical improvement was observed in 29 of 35 (82. 85%) patients. Ultrasound mea- surements showed that skin thickness was significantly reduced. No side effects were Conflicts of interest: None. observed during or after treatment. Conclusion Medium-dose UVA1 phototherapy is a highly effective, safe, and well-tolerated therapeutic modality for treatment of all types of LS.
    [Show full text]
  • European Guideline Chronic Pruritus Final Version
    EDF-Guidelines for Chronic Pruritus In cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Européenne des Médecins Spécialistes (UEMS) E Weisshaar1, JC Szepietowski2, U Darsow3, L Misery4, J Wallengren5, T Mettang6, U Gieler7, T Lotti8, J Lambert9, P Maisel10, M Streit11, M Greaves12, A Carmichael13, E Tschachler14, J Ring3, S Ständer15 University Hospital Heidelberg, Clinical Social Medicine, Environmental and Occupational Dermatology, Germany1, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Poland2, Department of Dermatology and Allergy Biederstein, Technical University Munich, Germany3, Department of Dermatology, University Hospital Brest, France4, Department of Dermatology, Lund University, Sweden5, German Clinic for Diagnostics, Nephrology, Wiesbaden, Germany6, Department of Psychosomatic Dermatology, Clinic for Psychosomatic Medicine, University of Giessen, Germany7, Department of Dermatology, University of Florence, Italy8, Department of Dermatology, University of Antwerpen, Belgium9, Department of General Medicine, University Hospital Muenster, Germany10, Department of Dermatology, Kantonsspital Aarau, Switzerland11, Department of Dermatology, St. Thomas Hospital Lambeth, London, UK12, Department of Dermatology, James Cook University Hospital Middlesbrough, UK13, Department of Dermatology, Medical University Vienna, Austria14, Department of Dermatology, Competence Center for Pruritus, University Hospital Muenster, Germany15 Corresponding author: Elke Weisshaar
    [Show full text]
  • Bullous Pemphigoid: Trigger and Predisposing Factors
    biomolecules Review Bullous Pemphigoid: Trigger and Predisposing Factors , , Francesco Moro * y , Luca Fania * y, Jo Linda Maria Sinagra, Adele Salemme and Giovanni Di Zenzo First Dermatology Clinic, IDI-IRCCS, Via Dei Monti di Creta 104, 00167 Rome, Italy; [email protected] (J.L.M.S.); [email protected] (A.S.); [email protected] (G.D.Z.) * Correspondence: [email protected] (F.M.); [email protected] (L.F.); Tel.: +39-(342)-802-0004 (F.M.) These authors have equally contributed to the manuscript. y Received: 7 September 2020; Accepted: 8 October 2020; Published: 10 October 2020 Abstract: Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal blistering disease provoked by autoantibodies directed against two hemidesmosomal proteins: BP180 and BP230. Its pathogenesis depends on the interaction between predisposing factors, such as human leukocyte antigen (HLA) genes, comorbidities, aging, and trigger factors. Several trigger factors, such as drugs, thermal or electrical burns, surgical procedures, trauma, ultraviolet irradiation, radiotherapy, chemical preparations, transplants, and infections may induce or exacerbate BP disease. Identification of predisposing and trigger factors can increase the understanding of BP pathogenesis. Furthermore, an accurate anamnesis focused on the recognition of a possible trigger factor can improve prognosis by promptly removing it. Keywords: bullous pemphigoid; autoimmune bullous disease; trigger factors; predisposing factors; etiopathogenesis 1. Introduction Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease, affecting predominantly elderly people. It is characterized by generalized pruritic urticarial plaques and tense subepithelial blisters. BP autoantibodies are directed mainly against two hemidesmosomal proteins, BP180 (also termed type XVII collagen) and BP230, which are components of the dermo-epidermal junction (DEJ) [1].
    [Show full text]
  • Bullous Pemphigoid/Pemphigus and Administration of the Pfizer/Biontech Vaccine (Comirnaty®). Introduction the Pfizer/Bionte
    Bullous Pemphigoid/Pemphigus and administration of the Pfizer/BioNTech vaccine (Comirnaty®). Introduction The Pfizer/BioNTech vaccine (Comirnaty®) is a COVID-19-mRNA-vaccine (nucleoside modified). It is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older. [1] The nucleoside-modified messenger RNA in Comirnaty® is formulated in lipid nanoparticles, which enable delivery of the nonreplicating RNA into host cells to direct transient expression of the SARS-CoV-2 S antigen. The mRNA codes for membrane-anchored, full-length Spike glycoprotein with two point mutations within the central helix. [1] Comirnaty® has been registered in Europe since December 21st, 2020. Bullous skin diseases are a group of dermatoses characterized by blisters and bullae in the skin and mucous membranes. The most common are pemphigus and bullous pemphigoid (BP). Pemphigus and bullous pemphigoid are autoantibody-mediated blistering skin diseases. In pemphigus, keratinocytes in epidermis and mucous membranes lose cell-cell adhesion, and in pemphigoid, the basal keratinocytes lose adhesion to the basement membrane. Bullous pemphigoid is a more common disease than pemphigus [2]. Bullous pemphigoid is the most common heterogeneous subepidermal autoimmune blistering disease (incidence 7 per million person year) [3,4], with an increasing prevalence after the age of 70, although it can also occur in the younger. It is characterized by auto-antibodies against different structural proteins of the hemidesmosomes in the epidermal basement membrane zone (EBMZ). Bullous pemphigoid typically causes severe pruritus with predominantly cutaneous lesions consisting of tense (fluid filled) bullae, erythema, and urticarial plaques.
    [Show full text]
  • Local Anesthetics
    Local Anesthetics Introduction and History Cocaine is a naturally occurring compound indigenous to the Andes Mountains, West Indies, and Java. It was the first anesthetic to be discovered and is the only naturally occurring local anesthetic; all others are synthetically derived. Cocaine was introduced into Europe in the 1800s following its isolation from coca beans. Sigmund Freud, the noted Austrian psychoanalyst, used cocaine on his patients and became addicted through self-experimentation. In the latter half of the 1800s, interest in the drug became widespread, and many of cocaine's pharmacologic actions and adverse effects were elucidated during this time. In the 1880s, Koller introduced cocaine to the field of ophthalmology, and Hall introduced it to dentistry Overwiev Local anesthetics (LAs) are drugs that block the sensation of pain in the region where they are administered. LAs act by reversibly blocking the sodium channels of nerve fibers, thereby inhibiting the conduction of nerve impulses. Nerve fibers which carry pain sensation have the smallest diameter and are the first to be blocked by LAs. Loss of motor function and sensation of touch and pressure follow, depending on the duration of action and dose of the LA used. LAs can be infiltrated into skin/subcutaneous tissues to achieve local anesthesia or into the epidural/subarachnoid space to achieve regional anesthesia (e.g., spinal anesthesia, epidural anesthesia, etc.). Some LAs (lidocaine, prilocaine, tetracaine) are effective on topical application and are used before minor invasive procedures (venipuncture, bladder catheterization, endoscopy/laryngoscopy). LAs are divided into two groups based on their chemical structure. The amide group (lidocaine, prilocaine, mepivacaine, etc.) is safer and, hence, more commonly used in clinical practice.
    [Show full text]
  • Pruritus: Scratching the Surface
    Pruritus: Scratching the surface Iris Ale, MD Director Allergy Unit, University Hospital Professor of Dermatology Republic University, Uruguay Member of the ICDRG ITCH • defined as an “unpleasant sensation of the skin leading to the desire to scratch” -- Samuel Hafenreffer (1660) • The definition offered by the German physician Samuel Hafenreffer in 1660 has yet to be improved upon. • However, it turns out that itch is, indeed, inseparable from the desire to scratch. Savin JA. How should we define itching? J Am Acad Dermatol. 1998;39(2 Pt 1):268-9. Pruritus • “Scratching is one of nature’s sweetest gratifications, and the one nearest to hand….” -- Michel de Montaigne (1553) “…..But repentance follows too annoyingly close at its heels.” The Essays of Montaigne Itch has been ranked, by scientific and artistic observers alike, among the most distressing physical sensations one can experience: In Dante’s Inferno, falsifiers were punished by “the burning rage / of fierce itching that nothing could relieve” Pruritus and body defence • Pruritus fulfils an essential part of the innate defence mechanism of the body. • Next to pain, itch may serve as an alarm system to remove possibly damaging or harming substances from the skin. • Itch, and the accompanying scratch reflex, evolved in order to protect us from such dangers as malaria, yellow fever, and dengue, transmitted by mosquitoes, typhus-bearing lice, plague-bearing fleas • However, chronic itch lost this function. Chronic Pruritus • Chronic pruritus is a common and distressing symptom, that is associated with a variety of skin conditions and systemic diseases • It usually has a dramatic impact on the quality of life of the affected individuals Chronic Pruritus • Despite being the major symptom associated with skin disease, our understanding of the pathogenesis of most types of itch is limited, and current therapies are often inadequate.
    [Show full text]